X
[{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Selected to Present TOTUM-854\u2019s Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valbiotis"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Reveals Positive TOTUM\u2022854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valbiotis"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM\u2022854 Clinical Study, Against High Blood Pressure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Valbiotis"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.
Lead Product(s):
TOTUM•854
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Totum-854
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 30, 2023
Details:
The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.
Lead Product(s):
TOTUM•854
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TOTUM•854
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
University of Avignon
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 12, 2021
Details:
Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Riom R&D platform.
Lead Product(s):
TOTUM-854
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TOTUM-854
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
University of Avignon
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 08, 2021